Currently out of the existing stock ratings of Gbola Amusa, 25 are a HOLD (23.36%), 71 are a BUY (66.36%), 11 are a SELL (10.28%).

Gbola Amusa

Work Performance Price Targets & Ratings Chart

Analyst Gbola Amusa, currently employed at CHARDAN CAPITAL, carries an average stock price target met ratio of 65.26% that have a potential upside of 60.9% achieved within 356 days.

Gbola Amusa’s has documented 219 price targets and ratings displayed on 26 stocks. The coverage is on Healthcare, Industrials sectors.

Most recent stock forecast was given on PASG, Passage Bio at 06-Aug-2023.

Wall Street Analyst Gbola Amusa

Analyst best performing recommendations are on AGTC (APPLIED GENETIC).
The best stock recommendation documented was for VYGR (VOYAGER THERAPEUTICS) at 12/9/2015. The price target of $20 was fulfilled within 7 days with a profit of $4.72 (19.09%) receiving and performance score of 27.28.

Average potential price target upside

of $57.93 (77.59%) on SLDB (SOLID BIOSCIENCES LLC).
of $41.05 (121.67%) on KRYS (KRYSTAL BIOTECH).
of $21.85 (61.92%) on ADVM (ADVERUM BIOTECHNOLOGIES).

ADVM Adverum Biotechnologies AXON Axon Enterprise ESPR Esperion Therapeutics FOLD Amicus Therapeutics KRYS Krystal Biotech LJPC La Jolla Pharmaceutical Co MDCO The Medicines Company MGTX MeiraGTx Holdings PLC MRNA Moderna ONCE Spark Therapeutics PASG Passage Bio PRVB Provention Bio QURE Uniqure NV REGN Regeneron Pharmaceuticals RGNX Regenxbio SAGE Sage Therapeutic SLDB Solid Biosciences LLC VYGR Voyager Therapeutics AGTC Applied Genetic IMVT Immunovant MCRB Seres Therapeutics TSHA Taysha Gene Therapies ABUS Arbutus Biopharma Corp FBRX Forte Biosciences VBLT Vascular Biogenics Ltd ISEE IVERIC bio

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Matthew Caufield (HC WAINWRIGHT)